A combination of ΓΔt cells and an oncolytic virus encoding an Anti-butyrophilin antibody

By engineering oncolytic viruses with anti-butyrophilin antibodies, the activation and antitumor activity of Vy9V82 T cells are enhanced, addressing the limitations of systemic antibody activation and improving tumor control.

WO2026234407A1PCT designated stage Publication Date: 2026-11-12INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2025/000199
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing immunotherapies face challenges in activating Vy9V82 T cells effectively due to systemic injection of agonistic antibodies targeting ubiquitously expressed butyrophilins, leading to potential off-target toxicities and limited efficacy, while oncolytic viruses struggle to potentiate the antitumor activity of these cells through canonical BTN/TCR axis.

Method used

Engineering oncolytic viruses with transgenes encoding an anti-butyrophilin antibody, such as anti-BTN3A, to activate Vy9V82 T cells specifically at tumor sites, enhancing their activation and antitumor activity.

Benefits of technology

The combination of armed oncolytic viruses and Vy9V82 T cells demonstrates improved tumor control by producing functional antibodies that activate and enhance the cytolytic function, cytokine production, and proliferation of Vy9V82 T cells in the tumor microenvironment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000032_0001
    Figure IMGF000032_0001
  • Figure IMGF000032_0002
    Figure IMGF000032_0002
  • Figure 00000054_0000
    Figure 00000054_0000
Patent Text Reader

Abstract

The therapeutic efficacy of oncolytic viruses relies on direct cytolytic properties, the vectorization of therapeutic transgenes and the activation of different mechanisms of the antitumor immune response. γδ T cells are important players of both antitumor and antiviral immunities and show increasing interest for cancer immunotherapy. The inventors sought to characterize how the human Vγ9Vδ2 subpopulation, which recognizes butyrophilins on stressed cells, reacts to tumor cells infected with different oncolytic viruses. In an in vivo model, they showed that a treatment combining an armed oncolytic virus with human Vγ9Vδ2 T cells was more efficient than either of the two treatments used alone. In particular, the present invention relates to a combination of γδ T cells and an oncolytic virus encoding an anti- butyrophilin antibody.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] A COMBINATION OF y8T CELLS AND AN ONCOLYTIC VIRUS ENCODING AN ANTI-BUTYROPHILIN ANTIBODY

[0002] FIELD OF THE INVENTION:

[0003] The invention is in the field of oncology. More particularly, the invention relates a combination of y8 T cells and an oncolytic virus encoding an anti-butyrophilin antibody.

[0004] BACKGROUND OF THE INVENTION:

[0005] The development of immunotherapies has revolutionized cancer treatment over the last decade. However, important challenges remain, including the identification of reliable prognostic markers for efficacy and toxicity, or the implementation of rational-based combinations to improve response rates1. Of the many immune cell types that have been associated with immunotherapy efficacy, the y8 T cells play a specific role with both innate and adaptive immune functions2. These cells express semi-invariant TCRs that can recognize conserved markers displayed on the surface stressed cells, for instance in the context of viral infection or malignant transformation3. They have an important function in polarizing favorably the antitumor immune response with the secretion of immunostimulatory cytokines (e.g. IFN-y) and display a potent cytolytic activity. These properties led several groups to exploit y8 T cells for adoptive cell therapy with native or engineered cells, or to develop strategies to activate them in situ4,5.

[0006] The Vy9V82 T cell subpopulation is predominant in the blood and rapidly recruited to sites of inflammation. Their TCR recognize the ubiquitously expressed butyrophilins (BTNs) that have been shown to translate at the cell surface the intracellular stress caused by the accumulation of exogenous or endogenous phosphoantigens6. Changes in the conformation of BTNs at the cell surface drive the activation of Vy9V82 T cells, which induces the secretion of pro-inflammatory cytokines and leads to the killing of the target cells. Among the strategies that have been developed to activate this population in the context of cancer treatment is the use of agonistic antibodies that bind to BTNs to provoke a change in conformation and a subsequent recognition by the Vy9V82 TCR7. The ICT01 antibody was shown to efficiently activate adoptively transferred Vy9V82 T cells in immunodeficient mice and showed a good safety profile when injected in macaques and in humans in a phase I / II trial8. However, the systemic injection of an agonistic antibody able to target proteins that are ubiquitously expressed may limit treatmentefficacy and possibly lead to off-target toxicities. The development of vectorization approaches to deliver it to tumor sites could thus help solving thus issues9.

[0007] Oncolytic virotherapy is an alternative immunotherapeutic approach that uses live-attenuated viruses which replication and cytotoxic activity are restricted to malignant cells, generally because of genetic alterations that affect cell cycle regulation and innate antiviral immunity pathways10,11. In addition to their lytic properties, these viruses have been demonstrated by us and others to activate a wide array of immune cells that are critical for the development of efficient antitumor immune responses12 l5. They can also be engineered with therapeutic transgenes which products will be specifically expressed at tumor sites where the viruses replicate10. These different properties make oncolytic viruses (OVs) particularly interesting when developing precision approaches in cancer immunotherapy. In line with the initial approval of the herpesvirus Talimogene laherparepvec in 2015 for the treatment of metastatic melanoma16, several viruses recently showed a good efficacy in early-phase clinical trials and were conditionally approved for use in patients with advanced cancers17,18.

[0008] Considering the critical functions of y8 T cells in both antiviral and antitumor immunity, the inventors wondered whether their activity could be potentiated by the use of OVs. Using three different viruses (measles virus, MV; vesicular stomatitis virus, VSV; vaccinia virus, VACV), they found that Vy9V82 T cells were poorly activated when cocultured with infected human tumor cells. Only MV induced a partial activation of these cells, but through a mechanism seemingly independent from the canonical BTN / TCR axis. To exploit the potential of y8 T cells in the context of oncolytic virotherapy, they engineered OVs with transgenes encoding for an anti-BTN agonistic antibody. They demonstrated that tumor cells of different origins infected by these armed OVs were able to produce a functional antibody in sufficient amount to activate Vy9V82 T cells in vitro in both 2D and 3D settings. They also showed that mice treated with a combination of an armed OV and adoptive transfer of Vy9V82 T cells showed better tumor control than mice treated with either treatment alone. Their findings demonstrate that OVs can be engineered to specifically promote the antitumor activity of Vy9V82 T cells in the tumor microenvironment and open the way to a new type of combination immunotherapy approaches.

[0009] SUMMARY OF THE INVENTION:

[0010] The invention relates to a combination of y8 T cells and an oncolytic virus encoding an anti-butyrophilin antibody. In particular, the present invention is defined by the claims.DETAILED DESCRIPTION OF THE INVENTION:

[0011] The therapeutic efficacy of oncolytic viruses relies on direct cytolytic properties, the vectorization of therapeutic transgenes and the activation of different mechanisms of the antitumor immune response. y8 T cells are important players of both antitumor and antiviral immunities and show increasing interest for cancer immunotherapy. The inventors sought to characterize how the human Vy9V82 subpopulation, which recognizes butyrophilins on stressed cells, reacts to tumor cells infected with different oncolytic viruses. The activation of y8 T lymphocytes was partly enhanced only after infection by an oncolytic strain of measles virus, but through an unidentified mechanism independent from the canonical TCR / butyrophilin axis. In order to improve the antitumor activity of Vy9V82 T cells in the context of an oncolytic infection, they inserted into the genomes of oncolytic Vaccinia Virus and Vesicular Stomatitis Virus the sequence of the agonistic anti-butyrophilin-3A (anti-BTN3 A) antibody 20.1 , previously described to promote tumor recognition and killing by y8 T cells. They demonstrate that tumor cells infected by these viruses produce functional antibodies that can bind to tumor cells and promote the activation and antitumor activity of y8 T cells in cocultures. In an in vivo model, they showed that a treatment combining an armed oncolytic virus with human Vy9V82 T cells was more efficient than either of the two treatments used alone. Their study shows that oncolytic viruses are appropriate vectors to produce agonistic antibodies in tumors and to potentiate the activity of antitumor y8 T lymphocytes in the tumor microenvironment.

[0012] The present invention relates to an oncolytic vaccinia virus encoding the agonistic anti-butyrophilin antibody for activating the antitumor properties of human of Vy9V82 T cells.

[0013] Antibody anti-butyrophilin

[0014] As used herein the term “butyrophilin” (BTN) refers to membrane proteins belonging to the immunoglobulin superfamily (Ig). The human butyrophilin family includes seven members that are subdivided into three subfamilies: BTN1, BTN2 and BTN3. The BTN1 subfamily contains only the prototypic single copy BTN 1 Al gene, the BTN2 contains two isoforms BTN2A1 and BTN2A2 and the BTN3 contains three isoforms BTN3A1, BTN3A2 and BTN3A3. BTN1A1 has a crucial function in the secretion of lipids into milk (Ogg et al. 2004) and collectively, BTN2 and BTN3 proteins are cell surface transmembrane glycoproteins, that act as regulators of immune responses.As used herein the term "antibody" or "immunoglobulin" have the same meaning, and will be used equally in the present invention. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. As such, the term antibody encompasses not only whole antibody molecules, but also antibody fragments as well as variants (including derivatives) of antibodies and antibody fragments. In natural antibodies, two heavy chains are linked to each other by disulfide bonds and each heavy chain is linked to a light chain by a disulfide bond. There are two types of light chain, lambda (1) and kappa (k). There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE. Each chain contains distinct sequence domains. The light chain includes two domains, a variable domain (VL) and a constant domain (CL). The heavy chain includes four domains, a variable domain (VH) and three constant domains (CHI, CH2 and CH3, collectively referred to as CH). The variable regions of both light (VL) and heavy (VH) chains determine binding recognition and specificity to the antigen. The constant region domains of the light (CL) and heavy (CH) chains confer important biological properties such as antibody chain association, secretion, trans-placental mobility, complement binding, and binding to Ec receptors (EcR). The Fv fragment is the N-terminal part of the Fab fragment of an immunoglobulin and consists of the variable portions of one light chain and one heavy chain. The specificity of the antibody resides in the structural complementarity between the antibody combining site and the antigenic determinant. Antibody combining sites are made up of residues that are primarily from the hypervariable or complementarity determining regions (CDRs). Occasionally, residues from nonhypervariable or framework regions (FR) can participate to the antibody binding site or influence the overall domain structure and hence the combining site. Complementarity Determining Regions or CDRs refer to amino acid sequences which together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site. The light and heavy chains of an immunoglobulin each have three CDRs, designated L-CDR1, L-CDR2, L- CDR3 and H-CDR1, H-CDR2, H-CDR3, respectively. An antigen-binding site, therefore, typically includes six CDRs, comprising the CDR set from each of a heavy and a light chain V region. Framework Regions (FRs) refer to amino acid sequences interposed between CDRs.

[0015] In one embodiment, the antibodies of the invention are monoclonal antibodies. As used herein, a “monoclonal antibody” in its various grammatical forms refers to a population of antibodiesthat contains only one species of antibody combining sites capable of immunoreacting with a particular epitope. A monoclonal antibody thus typically displays a single binding affinity for any epitope with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different epitope, e.g. a bispecific monoclonal antibody. Although historically a monoclonal antibody was produced by immortalization of a clonally pure immunoglobulin secreting cell line, a monoclonally pure population of antibody molecules can also be prepared by the methods of the present invention. Laboratory methods for preparing monoclonal antibodies are well known in the art (see, for example, Harlow et al., 1988). Monoclonal antibodies (mAbs) may be prepared by immunizing purified anti-butyrophilin antibody into a mammal, e.g. a mouse, rat, human and the like mammals. The antibody-producing cells in the immunized mammal are isolated and fused with myeloma or heteromyeloma cells to produce hybrid cells (hybridoma). The hybridoma cells producing the monoclonal antibodies are utilized as a source of the desired monoclonal antibody. This standard method of hybridoma culture is described in Kohler and Milstein (1975). While mAbs can be produced by hybridoma culture the invention is not to be so limited. Also contemplated is the use of mAbs produced by an expressing nucleic acid cloned from a hybridoma of this invention. That is, the nucleic acid expressing the molecules secreted by a hybridoma of this invention can be transferred into another cell line to produce a transformant. The transformant is genotypically distinct from the original hybridoma but is also capable of producing antibody molecules of this invention, including immunologically active fragments of whole antibody molecules, corresponding to those secreted by the hybridoma. See, for example, U.S. Pat. No. 4,642,334 to Reading; PCT Publication No.; European Patent Publications No. 0239400 to Winter et al. and No. 0125023 to Cabilly et al. Antibody generation techniques not involving immunisation are also contemplated such as for example using phage display technology to examine naive libraries (from non-immunised animals); see Barbas et al. (1992), and Waterhouse et al. (1993).

[0016] As used, the terms “chimeric antibody” refer to a genetically engineered fusion of parts of an animal antibody, typically a mouse antibody, with parts of a human antibody. Generally, chimeric antibodies contain approximately 33% mouse protein and 67% human protein. Developed to reduce the Human Anti-animal Antibodies response elicited by animal antibodies, they combine the specificity of the animal antibody with the efficient human immune system interaction of a human antibody.As used herein, the term “humanized antibody” refers to an antibody having variable region framework and constant regions from a human antibody but retains the CDRs of the animal antibody.

[0017] The humanized antibodies of the present invention may be produced by obtaining nucleic acid sequences encoding CDR domains, as previously described, constructing humanized antibodies expression vector by inserting them into an expression vector for animal cell having genes encoding (i) a heavy chain constant region identical to that of a human antibody and (ii) a light chain constant region identical to that of a human antibody, and expressing the genes by introducing the expression vector into an animal cell. The humanized antibody expression vector may be either of a type in which a gene encoding an antibody heavy chain and a gene encoding an antibody light chain exists on separate vectors or of a type in which both genes exist on the same vector (tandem type). In respect of easiness of construction of a humanized antibody expression vector, easiness of introduction into animal cells, and balance between the expression levels of antibody H and L chains in animal cells, humanized antibody expression vector of the tandem type is preferred. Examples of tandem type humanized antibody expression vector include pKANTEX93 (WO 97 / 10354), pEE18 and the like. Methods for producing humanized antibodies based on conventional recombinant DNA and gene transfection techniques are well known in the art (See, e. g., Riechmann L. et al. 1988; Neuberger MS. et al. 1985). Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO91 / 09967; U.S. Pat. Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan EA (1991); Studnicka GM et al. (1994); Roguska MA. et al. (1994)), and chain shuffling (U.S. Pat. No.5, 565, 332). The general recombinant DNA technology for preparation of such antibodies is also known (see European Patent Application EP 125023 and International Patent Application WO 96 / 02576).

[0018] As used herein, the term “antigen binding fragment” of an antibody refers to one or more fragments of an intact antibody that retain the ability to specifically binds to a given antigen (e.g., butyrophilin). Antigen biding functions of an antibody can be performed by fragments of an intact antibody. Examples of biding fragments encompassed within the term antigen biding fragment of an antibody include a Fab fragment, a monovalent fragment consisting of the VL,VH,CL and CHI domains; a Fab’ fragment, a monovalent fragment consisting of the VL,VH,CL,CH1 domains and hinge region; a F(ab’)2 fragment, a bivalent fragmentcomprising two Fab’ fragments linked by a disulfide bridge at the hinge region; an Fd fragment consisting of VH domains of a single arm of an antibody; a single domain antibody (sdAb) fragment (Ward et al., 1989 Nature 341:544-546), which consists of a VH domain or a VL domain; and an isolated complementary determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by an artificial peptide linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (ScFv); see, e.g., Bird et al., 1989 Science 242:423-426; and Huston et al., 1988 proc. Natl. Acad. Sci. 85:5879-5883). "dsFv" is a VH::VL heterodimer stabilised by a disulfide bond. Divalent and multivalent antibody fragments can form either spontaneously by association of monovalent scFvs, or can be generated by coupling monovalent scFvs by a peptide linker, such as divalent sc(Fv)2. Such single chain antibodies include one or more antigen biding portions or fragments of an antibody. These antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are screened for utility in the same manner as are intact antibodies. A unibody is another type of antibody fragment lacking the hinge region of IgG4 antibodies. The deletion of the hinge region results in a molecule that is essentially half the size of traditional IgG4 antibodies and has a univalent binding region rather than the bivalent biding region of IgG4 antibodies. Antigen binding fragments can be incorporated into single domain antibodies, SMIP, maxibodies, minibodies, intrabodies, diabodies, triabodies and tetrabodies (see, e.g., Hollinger and Hudson, 2005, Nature Biotechnology, 23, 9, 1126-1136). The term "diabodies" “tribodies” or “tetrabodies” refers to small antibody fragments with multivalent antigen-binding sites (2, 3 or four), which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Antigen biding fragments can be incorporated into single chain molecules comprising a pair of tandem Fv segments (VH-CH1-VH-CH1) Which, together with complementary light chain polypeptides, form a pair of antigen binding regions (Zapata et al., 1995 Protein Eng. 8(10); 1057-1062 and U.S. Pat. No. 5,641,870).

[0019] As used herein, the expression “fragment of an antibody” refers to a portion of said antibody comprising at least the antigen-binding domain. Said fragments are for example Fab, fabz, Fzabz)2 and Fv.As used herein, the term “Fab” denotes an antibody fragment having a molecular weight of about 50,000 and antigen binding activity, in which about a half of the N-terminal side of H chain and the entire L chain, among fragments obtained by treating IgG with a protease, papaine, are bound together through a disulfide bond.

[0020] As used herein, the term “F(ab' )2” refers to an antibody fragment having a molecular weight of about 100,000 and antigen binding activity, which is slightly larger than the Fab bound via a disulfide bond of the hinge region, among fragments obtained by treating IgG with a protease, pepsin.

[0021] As used herein, the term “Fab / ” refers to an antibody fragment having a molecular weight of about 50,000 and antigen binding activity, which is obtained by cutting a disulfide bond of the hinge region of the F(abz)2.

[0022] As used herein, the term “single chain Fv” (“scFv”) refers to a polypeptide is a covalently linked VH::VL heterodimer which is usually expressed from a gene fusion including VH and VL encoding genes linked by a peptide-encoding linker.

[0023] As used herein, the expression “derivative of an antibody” refers to an antibody which comprises the 6 CDRs of said antibody.

[0024] As used herein, the term “epitope” refers to a specific arrangement of amino acids located on a protein or proteins to which an antibody binds. Epitopes often consist of a chemically active surface grouping of molecules such as amino acids or sugar side chains, and have specific three-dimensional structural characteristics as well as specific charge characteristics. Epitopes can be linear or conformational, i.e., involving two or more sequences of amino acids in various regions of the antigen that may not necessarily be contiguous.

[0025] As used herein, the term “specificity” refers to the ability of an antibody to detectably bind an epitope presented on an antigen, such as butyrophilin, while having relatively little detectable reactivity with non- butyrophilin proteins or structures (such as other proteins presented on cancerous cell, or on other cell types). Specificity can be relatively determined by binding or competitive binding assays, using, e.g., Biacore instruments, as described elsewhere herein.Specificity can be exhibited by, e.g., an about 10:1, about 20:1, about 50:1, about 100:1, 10.000:1 or greater ratio of affinity / avidity in binding to the specific antigen versus nonspecific binding to other irrelevant molecules (in this case the specific antigen is butyrophilin). The term “affinity”, as used herein, means the strength of the binding of an antibody to an epitope. The affinity of an antibody is given by the dissociation constant Kd, defined as [Ab] x [Ag] / [Ab-Ag], where [Ab-Ag] is the molar concentration of the antibody-antigen complex, [Ab] is the molar concentration of the unbound antibody and [Ag] is the molar concentration of the unbound antigen. The affinity constant Ka is defined by 1 / Kd. Preferred methods for determining the affinity of mAbs can be found in Harlow, et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988), Coligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc, and Wiley Interscience, N.Y., (1992, 1993), and Muller, Meth. Enzymol. 92:589-601 (1983), which references are entirely incorporated herein by reference. One preferred and standard method well known in the art for determining the affinity of mAbs is the use of Biacore instruments.

[0026] As used herein, the terms "purified" and "isolated" mean that, when referring to a polypeptide (i.e. an antibody according to the invention) or to a nucleotide sequence, that the indicated molecule is present in the substantial absence of other biological macromolecules of the same type. The term "purified" as used herein preferably means at least 75% by weight, more preferably at least 85% by weight, more preferably still at least 95% by weight, and most preferably at least 98% by weight, of biological macromolecules of the same type are present.

[0027] An "isolated" nucleic acid molecule which encodes a particular polypeptide refers to a nucleic acid molecule which is substantially free of other nucleic acid molecules that do not encode the polypeptide; however, the molecule may include some additional bases or moieties which do not deleteriously affect the basic characteristics of the composition.

[0028] In some embodiment, the antibody of the present invention is an anti-butyrophilin-3A (anti-BTN3A) antibody. In particular, the anti-BTN3A antibody is the mAb 20.1.

[0029] As used herein “mAb 20.1" refers to an isolated anti-CD277 antibody which is obtainable from the hybridoma accessible under CNCM deposit number 1-4402. The expression "a derivative of mAb 20.1" refers to an anti-CD277 antibody which comprises the 6 CDRs of mAb 20.1.Oncolytic virus of the present invention

[0030] In some embodiments, the present invention relates to a vector for delivery of heterologous nucleic acids, wherein the nucleic acids encode the anti-butyrophilin antibody of the present invention (e.g. the anti-BTN3A).

[0031] As used herein, the term “vector” is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell. Numerous vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term “vector” includes an autonomously replicating plasmid or a virus. The term should also be construed to include non-plasmid and non-viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno- associated virus vectors, retroviral vectors, and the like. “Expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (e.g ., naked or contained in liposomes) and viruses (e.g, lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.

[0032] As used herein, the term “promoter” as used herein is defined as a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence. As used herein, the term “promoter / regulatory sequence” means a nucleic acid sequence, which is required for expression of a gene product operably linked to the promoter / regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements, which are required for expression of the gene product. The promoter / regulatory sequence may, for example, be one, which expresses the gene product in a tissue specific manner.

[0033] In some embodiments, the present invention provides an expression vector, comprising a nucleic acid encoding the anti-butyrophilin antibody described herein (e.g. anti-BTN3Aantibody). In some embodiments, the expression vector comprises DNA or RNA. In some embodiments, the expression vector is a mammalian expression vector.

[0034] Both prokaryotic and eukaryotic vectors can be used for expression of the anti-butyrophilin antibody (e.g. anti-BTN3A antibody). Prokaryotic vectors include constructs based on E. coli sequences (see, e.g., Makrides, Microbiol Rev 1996, 60:512-538). Non-limiting examples of regulatory regions that can be used for expression in E. coli include lac, trp, Ipp, phoA, recA, tac, T3, T7 and APL. Non-limiting examples of prokaryotic expression vectors may include the Agt vector series such as Agtl 1 (Huynh et al., in "DNA Cloning Techniques, Vol. I: A Practical Approach," 1984, (D. Glover, ed.), pp. 49-78, IRL Press, Oxford), and the pET vector series (Studier et al., Methods Enzymol 1990, 185:60-89). Prokaryotic host-vector systems cannot perform much of the post-translational processing of mammalian cells, however. Thus, eukaryotic host- vector systems may be particularly useful. A variety of regulatory regions can be used for expression of the anti-butyrophilin antibody (e.g. anti-BTN3A antibody) in mammalian host cells. For example, the SV40 early and late promoters, the cytomegalovirus (CMV) immediate early promoter, and the Rous sarcoma virus long terminal repeat (RSV-LTR) promoter can be used. Inducible promoters that may be useful in mammalian cells include, without limitation, promoters associated with the metallothionein II gene, mouse mammary tumor virus glucocorticoid responsive long terminal repeats (MMTV-LTR), the P-interferon gene, and the hsp70 gene (see, Williams et al., Cancer Res 1989, 49:2735-42; and Taylor et al., Mol Cell Biol 1990, 10:165-75). Heat shock promoters or stress promoters also may be advantageous for driving expression of the anti-butyrophilin antibody (e.g. anti-BTN3A antibody) in recombinant host cells.

[0035] In some embodiments, the expression vectors of the invention comprise a nucleic acid encoding the anti-butyrophilin antibody (e.g. anti-BTN3A antibody) (and / or additional agents), or a complement thereof, operably linked to an expression control region, or complement thereof, that is functional in a mammalian cell. The expression control region is capable of driving expression of the operably linked blocking and / or stimulating agent encoding nucleic acid such that the blocking and / or stimulating agent is produced in a human cell transformed with the expression vector. Expression control regions are regulatory polynucleotides (sometimes referred to herein as elements), such as promoters and enhancers, that influence expression of an operably linked nucleic acid. An expression control region of an expression vector of the invention is capable of expressing operably linked encoding nucleic acid in a human cell. Insome embodiment, the cell is a tumor cell. In another embodiment, the cell is a non-tumor cell. In some embodiment, the expression control region confers regulatable expression to an operably linked nucleic acid. A signal (sometimes referred to as a stimulus) can increase or decrease expression of a nucleic acid operably linked to such an expression control region. Such expression control regions that increase expression in response to a signal are often referred to as inducible. Such expression control regions that decrease expression in response to a signal are often referred to as repressible. Typically, the amount of increase or decrease conferred by such elements is proportional to the amount of signal present; the greater the amount of signal, the greater the increase or decrease in expression. In some embodiment, the present invention contemplates the use of inducible promoters capable of effecting high level of expression transiently in response to a cue. For example, when in the proximity of a tumor cell, a cell transformed with an expression vector for the anti-butyrophilin antibody (e.g. anti-BTN3A antibody) (and / or additional agents) comprising such an expression control sequence is induced to transiently produce a high level of the agent by exposing the transformed cell to an appropriate cue. Illustrative inducible expression control regions include those comprising an inducible promoter that is stimulated with a cue such as a small molecule chemical compound. Particular examples can be found, for example, in U.S. Pat. Nos. 5,989,910, 5,935,934, 6,015,709, and 6,004,941 , each of which is incorporated herein by reference in its entirety. Expression control regions and locus control regions include full-length promoter sequences, such as native promoter and enhancer elements, as well as subsequences or polynucleotide variants which retain all or part of full-length or non-variant function. As used herein, the term "functional" and grammatical variants thereof, when used in reference to a nucleic acid sequence, subsequence or fragment, means that the sequence has one or more functions of native nucleic acid sequence (e.g., non-variant or unmodified sequence).

[0036] In some embodiments the anti-butyrophilin antibody of the invention (e.g. anti-BTN3A antibody) is or can be secreted.

[0037] Expression systems functional in human cells are well known in the art, and include viral systems. Generally, a promoter functional in a human cell is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and typically a TATA box located 25-30 base pairs upstream of the transcription initiation site. The TATA box is thought to directRNA polymerase II to begin RNA synthesis at the correct site. A promoter will also typically contain an upstream promoter element (enhancer element), typically located within 100 to 200 base pairs upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter. Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-translational cleavage and polyadenylation. Examples of transcription terminator and polyadenylation signals include those derived from SV40. Introns may also be included in expression constructs. There are a variety of techniques available for introducing nucleic acids into viable cells. Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, polymer-based systems, DEAE-dextran, viral transduction, the calcium phosphate precipitation method, etc. For in vivo gene transfer, a number of techniques and reagents may also be used, including liposomes; natural polymer-based delivery vehicles, such as chitosan and gelatin; viral vectors are also suitable for in vivo transduction. In some situations, it is desirable to provide a targeting agent, such as an antibody or ligand specific for a tumor cell surface membrane protein. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and / or to facilitate uptake, e.g., capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu et al, J. Biol. Chem. 262, 4429- 4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). Where appropriate, gene delivery agents such as, e.g., integration sequences can also be employed. Numerous integration sequences are known in the art (see, e.g., Nunes-Duby et al., Nucleic Acids Res. 26:391 -406, 1998; Sadwoski, J. Bacterid., 165:341-357, 1986; Bestor, Cell, 122(3):322-325, 2005; Plasterk et al., TIG 15:326-332, 1999; Kootstra et al., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). These include recombinases and transposases. Examples include Cre (Sternberg and Hamilton, J. Mol. Biol., 150:467-486, 1981 ), lambda (Nash, Nature, 247, 543-545, 1974), Flp (Broach, et al., Cell, 29:227-234, 1982), R(Matsuzaki, etal., J. Bacteriology, 172:610-618, 1990), cpC31(see, e.g., Groth et al, J. Mol. Biol. 335:667-678, 2004), sleeping beauty, transposases of the mariner family (Plasterk et al., supra), and components for integrating viruses such as AAV, retroviruses, lentivirus having components that provide for virus integration such as the LTR sequences of retroviruses or lentivirus and the ITR sequences of AAV (Kootstra et al., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). In addition, direct and targeted genetic integration strategies may be used to insert nucleic acid sequences encoding the anti-butyrophilin antibody (e.g. anti-BTN3A antibody) including CRISPR / CAS9, zinc finger, TALEN, and meganuclease gene-editing technologies.

[0038] The present invention relates to an isolated oncolytic virus encoding an anti-butyrophilin antibody, which activates the cytolytic function, cytokine production and proliferation of Vy9V82 T cells. These functions are antitumoral and in particular allow to activate the antitumor functions of y8T cells.

[0039] By activating the cytolytic function of Vy9V82 T cells, it is meant that a significant increase of the cytotoxicity of Vy9V82 T cells, i.e. a significant increase of the specific lysis of the target cells by Vy9V82 T cells, is observed.

[0040] By increasing the cytokine production by Vy9V82 T cells, it is meant that a significant increase of the cytokine production by Vy9V82 T cells is observed, as compared to control Vy9V82 T cells (i.e. non stimulated and non treated).

[0041] By increasing the proliferation of Vy9V82 T cells, it is meant that a significant increase of the proliferation of Vy9V82 T cells is observed, as compared to control Vy9V82 T cells (i.e. non stimulated and non treated).

[0042] As used herein, the term "oncolytic virus" refers to a virus capable of selectively replicating in cells (e.g a cancer cell) with the aim of slowing the growth and / or lysing said cell, either in vitro or in vivo. Typically, an oncolytic virus contains a viral genome packaged into a viral particle (or virion) and is infectious (i.e. capable of infecting and entering into a host cell or subject). As used herein, this term encompasses DNA or NA vector (depending on the virus in question) as well as viral particles generated thereof.

[0043] In some embodiment, the oncolytic virus is an expression vector.In one aspect, the invention provides expression vectors for the expression of the anti-butyrophilin antibody (e.g. anti-BTN3A antibody) (and / or additional agents) that are viral vectors. Many viral vectors useful for gene therapy are known (see, e.g., Lundstrom, Trends Biotechnol., 21 : 1 17, 122, 2003. Illustrative viral vectors include those selected from vesicular stomatitis virus (VSV), lentivirus, (LV), retroviruses (RV), adenoviruses (AV), adeno-associated viruses (AAV) or a virus from the same families, measles virus (MV), herpesvirus, vaccinia virus (VV), herpesvirus (HSV), myxoma virus, reovirus, parvovirus, mumps virus and a viruses though other viral vectors may also be used. For in vivo uses, viral vectors that do not integrate into the host genome are suitable, such as adenoviruses. Illustrative types of a viruses include Sindbis virus, Venezuelan equine encephalitis (VEE) virus, Semliki Forest virus (SFV), HSV, enterovirus, paramyxovirus, poxvirus, rhabdovirus. For in vitro uses, viral vectors that integrate into the host genome are suitable, such as retroviruses, AAV, lentivirus. In some embodiments, the invention provides methods of transducing a human cell in vivo, comprising contacting a solid tumor in vivo with a viral vector of the invention.

[0044] In a particular embodiment, the viral vector of the invention is a measles virus (MV). In a particular embodiment, the viral vector of the invention is a vesicular stomatitis virus (VSV). In a particular embodiment, the viral vector of the invention is a recombinant vaccinia virus (W).

[0045] In some embodiments, the present invention provides a host cell, comprising the expression vector comprising the anti-butyrophilin antibody described herein (e.g. anti-BTN3A antibody).

[0046] Expression vectors can be introduced into host cells for producing anti-butyrophilin antibody as described herein (e.g. anti-BTN3A antibody). Cells may be cultured in vitro or genetically engineered, for example. Useful mammalian host cells include, without limitation, cells derived from humans, monkeys, and rodents (see, for example, Kriegler in "Gene Transfer and Expression: A Laboratory Manual," 1990, New York, Freeman & Co.). These include monkey kidney cell lines transformed by SV40 {e.g., COS-7, ATCC CRL 1651 ); human embryonic kidney lines {e.g., 293, 293-EBNA, or 293 cells subcloned for growth in suspension culture, Graham et al., J Gen Virol 1977, 36:59); baby hamster kidney cells {e.g., BHK, ATCC CCL 10); Chinese hamster ovary-cells-DHFR {e.g., CHO, Urlaub and Chasin, Proc Natl Acad Sci USA 1980, 77:4216); DG44 CHO cells, CHO-K1 cells, mouse Sertoli cells (Mather, BiolReprod 1980, 23:243-251); mouse fibroblast cells {e.g., NIH-3T3), monkey kidney cells (e.g., CV1 ATCC CCL 70); African green monkey kidney cells, (e.g., VERO-76, ATCC CRL-1587); human cervical carcinoma cells (e.g., HELA, ATCC CCL 2); canine kidney cells (e.g., MDCK, ATCC CCL 34); buffalo rat liver cells (e.g., BRL 3 A, ATCC CRL 1442); human lung cells (e.g., W138, ATCC CCL 75); human liver cells (e.g., Hep G2, HB 8065); and mouse mammary tumor cells (e.g., MMT 060562, ATCC CCL51). Illustrative cancer cell types for expressing anti-butyrophilin antibody described herein (e.g. anti-BTN3A antibody) include mouse fibroblast cell line, NIH3T3, mouse Lewis lung carcinoma cell line, LLC, mouse mastocytoma cell line, P815, mouse lymphoma cell line, EL4 and its ovalbumin transfectant, E.G7, mouse melanoma cell line, B16E10, mouse fibrosarcoma cell line, MC57, and human small cell lung carcinoma cell lines, SCLC#2 and SCLC#7.

[0047] Gene delivery viral vectors useful in the practice of the present invention can be constructed utilizing methodologies well known in the art of molecular biology. Typically, viral vectors carrying transgenes are assembled from polynucleotides encoding the transgene, suitable regulatory elements and elements necessary for production of viral proteins which mediate cell transduction.

[0048] Host cells can be obtained from normal or affected subjects, including healthy humans, cancer patients, and patients with an infectious disease, private laboratory deposits, public culture collections such as the American Type Culture Collection, or from commercial suppliers.

[0049] Common expression systems include E. coli host cells and plasmid vectors, insect host cells and Baculovirus vectors, and mammalian host cells and vectors. Other examples of host cells include, without limitation, prokaryotic cells (such as bacteria) and eukaryotic cells (such as yeast cells, mammalian cells, insect cells, plant cells, etc.). Specific examples include E. coli, Kluyveromyces or Saccharomyces yeasts, mammalian cell lines (e.g., Vero cells, CHO cells, 3T3 cells, COS cells, etc.) as well as primary or established mammalian cell cultures (e.g., produced from lymphoblasts, fibroblasts, embryonic cells, epithelial cells, nervous cells, adipocytes, etc.). Examples also include mouse SP2 / 0-Agl4 cell (ATCC CRL1581), mouse P3X63-Ag8.653 cell (ATCC CRL1580), CHO cell in which a dihydrofolate reductase gene (hereinafter referred to as "DHFR gene") is defective, rat YB2 / 3HL.P2.G11.16Ag.2O cell (ATCC CRL 1662, hereinafter referred to as "YB2 / 0 cell"), and the like.Cells that can be used for production of the anti-butyrophilin antibody describes herein (e.g. anti-BTN3A antibody) in vitro, ex vivo, and / or in vivo include, without limitation, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells (e.g., as obtained from bone marrow), umbilical cord blood, peripheral blood, fetal liver, etc. The choice of cell type depends on the type of tumor or infectious disease being treated or prevented, and can be determined by one of skill in the art.

[0050] V / 9V62 of the present invention

[0051] The inventors demonstrate the activation of Vy9V82 T cells against a variety of tumor cells. They show that this activation resulted in tumor cell killing by Vy9V82 T cells both in 2D and 3D culture systems.

[0052] As used herein, the term “White blood cells” refers to cells of the immune system involved in defending the body against pathogens. Among these cells, lymphocytes, monocytes, and dendritic cells can be cited. Monocytes may migrate from the bloodstream to other tissues and differentiate into tissue resident macrophages or dendritic cells. Dendritic cells play a role as antigen presenting cells (APC) that activate lymphocytes. Among lymphocytes, T cells can be divided into y8 T cells and a0 T cells.

[0053] As used herein, the term “Gamma delta T cells” (y8 T cells) refer to T cells that have a y8 T-cell receptor (TCR) on their surface. y8 T cells have a TCR that is made up of one y (gamma) chain and one 8 (delta) chain. Their highest abundance is in the gut mucosa, within a population of lymphocytes known as intraepithelial lymphocytes (lELs).

[0054] In some embodiment, the y8 T cells are Vy9V82 T cells.

[0055] As used herein, the term “Vy9V62 T cells” refers to important effectors of the immune defense. They lyse directly pathogen infected or abnormal cells. In addition, they regulate immune responses by inducing dendritic cell (DC) maturation as well as the isotypic switching and immunoglobulin production. This important cell platform of the immune system is strictly regulated by surface receptors, chemokines and cytokines.Treatment of the present invention:

[0056] A further object of the present invention relates to a method of treatment of cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody.

[0057] In particular, the present invention relates to a method of treatment of cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the combination of an oncolytic virus encoding the mAb 20.1 obtainable from the hybridoma accessible under CNCM deposit number 1-4402 and of Vy9Vb2 T cells.

[0058] The present invention also relates to the combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody for use in therapy.

[0059] In some embodiment, the present invention relates to a vaccine for the treatment of a cancer comprising a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody.

[0060] As used herein, the term “subject” refers to any mammals, such as a rodent, a feline, a canine, and a primate. Particularly, in the present invention, the subject is a human afflicted with or susceptible to be afflicted with cancer.

[0061] As used herein, the term "cancer" has its general meaning in the art and refers to a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. The term "cancer" further encompasses both primary and metastatic cancers. Examples of cancers that may treated by methods and compositions of the invention include, but are not limited to, cancer cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus. In addition, the cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecularadenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; non encapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous; adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; paget's disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w / squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; and roblastoma, malignant; Sertoli cell carcinoma; leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extramammary paraganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malign melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brennertumor, malignant; phyllodestumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; strumaovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma; odontogenic tumor, malignant; ameloblasticodontosarcoma; ameloblastoma, malignant; ameloblasticfibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; ependymoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; medulloblastoma, glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor,malignant; malignant lymphoma; Hodgkin's disease; Hodgkin's lymphoma; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specified non-Hodgkin’s lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocyticleukemia; mast cell leukemia; megakaryoblasticleukemia; myeloid sarcoma; and hairy cell leukemia.

[0062] As used herein, the term “metastasis” or “tumor metastasis” is meant the spread of cancer from its primary site to other places in the body. Cancer cells can break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream, and grow in a distant focus (metastasize) in normal tissues elsewhere in the body. Metastasis can be local or distant. Metastasis is a sequential process, contingent on tumor cells breaking off from the primary tumor, traveling through the bloodstream or lymphatics, and stopping at a distant site. At the new site, the cells establish a blood supply and can grow to form a life-threatening mass. In certain embodiments, the term metastatic tumor refers to a tumor that is capable of metastasizing, but has not yet metastasized to tissues or organs elsewhere in the body. In certain embodiments, the term metastatic tumor refers to a tumor that has metastasized to tissues or organs elsewhere in the body.

[0063] As used herein, the terms “treating” or “treatment” refer to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of subject at risk of contracting the disease or suspected to have contracted the disease as well as subject who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse. The treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment. By "therapeutic regimen" is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy. A therapeutic regimen may include an induction regimen and a maintenance regimen. The phrase "induction regimen" or "induction period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease. The general goal of an induction regimen is to provide a highlevel of drug to a subject during the initial period of a treatment regimen. An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both. The phrase "maintenance regimen" or "maintenance period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years). A maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., pain, disease manifestation, etc.]).

[0064] As used herein the terms "administering" or "administration" refer to the act of injecting or otherwise physically delivering a substance as it exists outside the body (e.g., the combination of the present invention) into the subject, such as by mucosal, intradermal, intravenous, subcutaneous, intramuscular delivery and / or any other method of physical delivery described herein or known in the art. When a disease, or a symptom thereof, is being treated, administration of the substance typically occurs after the onset of the disease or symptoms thereof. When a disease or symptoms thereof, are being prevented, administration of the substance typically occurs before the onset of the disease or symptoms thereof.

[0065] A “therapeutically effective amount” is intended for a minimal amount of active agent which is necessary to impart therapeutic benefit to a subject. For example, a "therapeutically effective amount" to a subject is such an amount which induces, ameliorates or otherwise causes an improvement in the pathological symptoms, disease progression or physiological conditions associated with or resistance to succumbing to a disorder. It will be understood that the total daily usage of the compounds of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidentialwith the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. However, the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day. Typically, the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient. An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg / kg to about 20 mg / kg of body weight per day, especially from about 0.001 mg / kg to 7 mg / kg of body weight per day.

[0066] The combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody of the present invention as described above may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions. "Pharmaceutically" or "pharmaceutically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle, alone or in combination with another active principle, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings. Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms. Typically, the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions. Thepharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The polypeptide (or nucleic acid encoding thereof) can be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin. Sterile injectable solutions are prepared by incorporating the active polypeptides in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

[0067] Combined preparation:

[0068] As used herein, the terms “combined treatment”, “combined therapy” or “therapy combination” refer to a treatment that uses more than one medication. The combined therapy may be dual therapy or bi-therapy.

[0069] As used herein, the term “administration simultaneously” refers to administration of 2 active ingredients by the same route and at the same time or at substantially the same time. The term “administration separately” refers to an administration of 2 active ingredients at the same time or at substantially the same time by different routes. The term “administration sequentially” refers to an administration of 2 active ingredients at different times, the administration route being identical or different.

[0070] In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) a classical treatment as a combined preparation for use in the treatment of cancer.In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) a classical treatment as a combined preparation for simultaneous, separate or sequential use for treating a subject suffering from a cancer

[0071] As used herein, the term “classical treatment” refers to any compound, natural or synthetic, used for the treatment of cancer.

[0072] In a particular embodiment, the classical treatment is chosen among radiation therapy, antibody therapy, immunotherapy or chemotherapy.

[0073] In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) immunotherapy as a combined preparation according to the invention for simultaneous, separate or sequential use for treating a subject suffering from a cancer.

[0074] In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) immunotherapy as a combined preparation according to the invention for simultaneous, separate or sequential use for improving cancer immunotherapy in a subject suffering from a cancer.

[0075] As used herein, the term “immunotherapy” has its general meaning in the art and refers to the treatment that consists in administering an immunogenic agent i.e. an agent capable of inducing, enhancing, suppressing or otherwise modifying an immune response. In a particular embodiment, the immunotherapy consists of use of an immune check point inhibitor as described above.

[0076] In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) chemotherapy as a combined preparation according to the invention for simultaneous, separate or sequential use for treating a subject suffering from a cancer.

[0077] In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) chemotherapy as a combined preparation according to theinvention for simultaneous, separate or sequential use for improving cancer chemoherapy in a subject suffering from a cancer.

[0078] As used herein, the term "chemotherapeutic agent" refers to chemical compounds that are effective in inhibiting tumor growth. Examples of chemotherapeutic agents include multkinase inhibitors such as sorafenib and sunitinib, alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimus tine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as the enediyne antibiotics (e.g. calicheamicin, especially calicheamicin (11 and calicheamicin 211, see, e.g., Agnew Chem Inti. Ed. Engl. 33: 183-186 (1994); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, canninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino- doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idanrbicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptomgrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5 -fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti- adrenals such asaminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defo famine; demecolcine; diaziquone; elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pento statin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; rhizoxin; sizofiran; spirogennanium; tenuazonic acid; triaziquone; 2, 2', 2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridinA and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobromtol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g. paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.].) and doxetaxel (TAXOTERE®, Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisp latin and carbop latin; vinblastine; platinum; etoposide (VP- 16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-1 1 ; topoisomerase inhibitor RFS 2000; difhroromethylornithine (DMFO); retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are antihormonal agents that act to regulate or inhibit honnone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY1 17018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are antimitotic agents such as monomethyl auristatin E (MMAE).

[0079] In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) radiation therapy as a combined preparation according to the invention for simultaneous, separate or sequential use for treating a subject suffering from a cancer.

[0080] In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) radiation therapy as a combined preparation according to the invention for simultaneous, separate or sequential use for improving cancer radiation therapy in a subject suffering from a cancer.As used herein, the terms “radiation therapy” or “radiotherapy” have their general meaning in the art and refers the treatment of cancer with ionizing radiation. Ionizing radiation deposits energy that injures or destroys cells in the area being treated (the target tissue) by damaging their genetic material, making it impossible for these cells to continue to grow. One type of radiation therapy commonly used involves photons, e.g. X-rays. Depending on the amount of energy they possess, the rays can be used to destroy cancer cells on the surface of or deeper in the body. The higher the energy of the x-ray beam, the deeper the x-rays can go into the target tissue. Linear accelerators and betatrons produce x-rays of increasingly greater energy. The use of machines to focus radiation (such as x-rays) on a cancer site is called external beam radiation therapy. Gamma rays are another form of photons used in radiation therapy. Gamma rays are produced spontaneously as certain elements (such as radium, uranium, and cobalt 60) release radiation as they decompose, or decay. In some embodiments, the radiation therapy is external radiation therapy. Examples of external radiation therapy include, but are not limited to, conventional external beam radiation therapy; three-dimensional conformal radiation therapy (3D-CRT), which delivers shaped beams to closely fit the shape of a tumor from different directions; intensity modulated radiation therapy (IMRT), e.g., helical tomotherapy, which shapes the radiation beams to closely fit the shape of a tumor and also alters the radiation dose according to the shape of the tumor; conformal proton beam radiation therapy; image-guided radiation therapy (IGRT), which combines scanning and radiation technologies to provide real time images of a tumor to guide the radiation treatment; intraoperative radiation therapy (IORT), which delivers radiation directly to a tumor during surgery; stereotactic radiosurgery, which delivers a large, precise radiation dose to a small tumor area in a single session; hyperfractionated radiation therapy, e.g., continuous hyperfractionated accelerated radiation therapy (CHART), in which more than one treatment (fraction) of radiation therapy are given to a subject per day; and hypoffactionated radiation therapy, in which larger doses of radiation therapy per fraction is given but fewer fractions.

[0081] In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) immune checkpoint inhibitor as a combined preparation according to the invention for simultaneous, separate or sequential use for treating a subject suffering from a cancer.In a particular embodiment, i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) immune checkpoint inhibitor as a combined preparation according to the invention for simultaneous, separate or sequential use for improving cancer immunotherapy in a subject suffering from a cancer.

[0082] As used herein, the term "immune checkpoint inhibitor" refers to molecules that totally or partially reduce, inhibit, interfere with or modulate one or more immune checkpoint proteins.

[0083] As used herein, the term "immune checkpoint protein" has its general meaning in the art and refers to a molecule that is expressed by T cells in that either turn up a signal (stimulatory checkpoint molecules) or turn down a signal (inhibitory checkpoint molecules) or turn down a signal (inhibitory checkpoint molecules). Immune checkpoint molecules are recognized in the art to constitute immune checkpoint pathways similar to the CTLA-4 and PD-1 dependent pathways (see e.g. Pardoll, 2012. Nature Rev Cancer 12:252-264; Mellman et al., 2011. Nature 480:480- 489). Examples of stimulatory checkpoint include CD27 CD28 CD40, CD122, CD 137, 0X40, GITR, and ICOS. Examples of inhibitory checkpoint molecules include A2AR, B7-H3, B7-H4, BTLA, CTLA-4, CD277, IDO, KIR, PD-1, LAG-3, TIM-3 and VISTA. The Adenosine A2A receptor (A2AR) is regarded as an important checkpoint in cancer therapy because adenosine in the immune microenvironment, leading to the activation of the A2a receptor, is negative immune feedback loop and the tumor microenvironment has relatively high concentrations of adenosine. B7-H3, also called CD276, was originally understood to be a co-stimulatory molecule but is now regarded as co-inhibitory. B7-H4, also called VTCN1, is expressed by tumor cells and tumor-associated macrophages and plays a role in tumour escape. B and T Lymphocyte Attenuator (BTLA) and also called CD272, has HVEM (Herpesvirus Entry Mediator) as its ligand. Surface expression of BTLA is gradually downregulated during differentiation of human CD8+ T cells from the naive to effector cell phenotype, however tumor-specific human CD8+ T cells express high levels of BTLA. CTLA-4, Cytotoxic T-Lymphocyte-Associated protein 4 and also called CD 152. Expression of CTLA-4 on Treg cells serves to control T cell proliferation. IDO, Indoleamine 2, 3 -dioxygenase, is a tryptophan catabolic enzyme. A related immune-inhibitory enzymes. Another important molecule is TDO, tryptophan 2,3-dioxygenase. IDO is known to suppress T and NK cells, generate and activate Tregs and myeloid-derived suppressor cells, and promote tumour angiogenesis. KIR, Killercell Immunoglobulin-like Receptor, is a receptor for MHC Class I molecules on Natural Killer cells. LAG3, Lymphocyte Activation Gene-3, works to suppress an immune response by actionto Tregs as well as direct effects on CD8+ T cells. PD-1, Programmed Death 1 (PD-1) receptor, has two ligands, PD-L1 and PD-L2. This checkpoint is the target of Merck & Co.'s melanoma drug Keytruda, which gained FDA approval in September 2014. An advantage of targeting PD-1 is that it can restore immune function in the tumor microenvironment. TIM-3, short for T-cell Immunoglobulin domain and Mucin domain 3, expresses on activated human CD4+ T cells and regulates Thl and Th 17 cytokines. TIM-3 acts as a negative regulator of Thl / Tcl function by triggering cell death upon interaction with its ligand, galectin-9. VISTA, Short for V-domain Ig suppressor of T cell activation, VISTA is primarily expressed on hematopoietic cells so that consistent expression of VISTA on leukocytes within tumors may allow VISTA blockade to be effective across a broad range of solid tumors. Tumor cells often take advantage of these checkpoints to escape detection by the immune system. Thus, inhibiting a checkpoint protein on the immune system may enhance the antitumor T-cell response.

[0084] In some embodiments, an immune checkpoint inhibitor refers to any compound inhibiting the function of an immune checkpoint protein. Inhibition includes reduction of function and full blockade. In some embodiments, the immune checkpoint inhibitor could be an antibody, synthetic or native sequence peptides, small molecules or aptamers which bind to the immune checkpoint proteins and their ligands.

[0085] In a particular embodiment, the immune checkpoint inhibitor is an antibody.

[0086] Typically, antibodies are directed against A2AR, B7-H3, B7-H4, BTLA, CTLA-4, CD277, IDO, KIR, PD-1, LAG-3, TIM-3 or VISTA.

[0087] In a particular embodiment, the immune checkpoint inhibitor is an anti-PD-1 antibody such as described in WO2011082400, W02006121168, W02015035606, W02004056875, W02010036959, W02009114335, W02010089411, WO2008156712, WO2011110621, WO2014055648 and WO2014194302. Examples of anti-PD-1 antibodies which are commercialized: Nivolumab (Opdivo®, BMS), Pembrolizumab (also called Lambrolizumab, KEYTRUDA® or MK-3475, MERCK).

[0088] In some embodiments, the immune checkpoint inhibitor is an anti-PD-Ll antibody such as described in WO2013079174, W02010077634, W02004004771, WO2014195852, W02010036959, WO2011066389, W02007005874, W02015048520, US8617546 andWO2014055897. Examples of anti-PD-Ll antibodies which are on clinical trial: Atezolizumab (MPDL3280A, Genentech / Roche), Durvalumab (AZD9291, AstraZeneca), Avelumab (also known as MSB0010718C, Merck) and BMS-936559 (BMS).

[0089] In some embodiments, the immune checkpoint inhibitor is an anti-PD-L2 antibody such as described in US7709214, US7432059 and US8552154.

[0090] In the context of the invention, the immune checkpoint inhibitor inhibits Tim-3 or its ligand.

[0091] In a particular embodiment, the immune checkpoint inhibitor is an anti-Tim-3 antibody such as described in WO03063792, WO2011155607, WO2015117002, WO2010117057 and WO2013006490.

[0092] In some embodiments, the immune checkpoint inhibitor is a small organic molecule.

[0093] The term "small organic molecule" as used herein, refers to a molecule of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macro molecules (e. g. proteins, nucleic acids, etc.). Typically, small organic molecules range in size up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.

[0094] Typically, the small organic molecules interfere with transduction pathway of A2AR, B7-H3, B7-H4, BTLA, CTLA-4, CD277, IDO, KIR, PD-1, LAG-3, TIM-3 or VISTA.

[0095] In a particular embodiment, small organic molecules interfere with transduction pathway of PD-1 and Tim-3. For example, they can interfere with molecules, receptors or enzymes involved in PD-1 and Tim-3 pathway.

[0096] In a particular embodiment, the small organic molecules interfere with Indoleamine-pyrrole 2, 3 -dioxygenase (IDO) inhibitor. IDO is involved in the tryptophan catabolism (Liu et al 2010, Vacchelli et al 2014, Zhai et al 2015). Examples of IDO inhibitors are described in WO 2014150677. Examples of IDO inhibitors include without limitation 1-methyl-tryptophan (IMT), P- (3-benzofuranyl)-alanine, P-(3-benzo(b)thienyl)-alanine), 6-nitro-tryptophan, 6-fluoro-tryptophan, 4-methyl-tryptophan, 5 -methyl tryptophan, 6-methyl-tryptophan, 5-methoxy-tryptophan, 5 -hydroxy-tryptophan, indole 3-carbinol, 3,3'- diindolylmethane,epigallocatechin gallate, 5-Br-4-Cl-indoxyl 1,3 -diacetate, 9- vinylcarbazole, acemetacin, 5-bromo-tryptophan, 5 -bromoindoxyl diacetate, 3- Amino-naphtoic acid, pyrrolidine dithiocarbamate, 4-phenylimidazole a brassinin derivative, a thiohydantoin derivative, a P-carboline derivative or a brassilexin derivative. In a particular embodiment, the IDO inhibitor is selected from 1 -methyl -tryptophan, P-(3- benzofuranyl)-alanine, 6-nitro-L-tryptophan, 3-Amino-naphtoic acid and P-[3- benzo(b)thienyl] -alanine or a derivative or prodrug thereof.

[0097] In a particular embodiment, the inhibitor of IDO is Epacadostat, (INCB24360, INCB024360) has the following chemical formula in the art and refers to -N-(3-bromo-4-fIuorophenyl)-N'-hydroxy-4- { [2-(sulfamoylamino)-ethyl] amino } - 1 ,2 ,5 -oxadiazole-3 carboximidamide :

[0098]

[0099] In a particular embodiment, the inhibitor is BGB324, also called R428, such as described in W02009054864, refers to lH-l,2,4-Triazole-3,5-diamine, l-(6,7-dihydro-5H-benzo[6,7]cyclohepta[l,2-c]pyridazin-3-yl)-N3-[(7S)-6,7,8,9-tetrahydro-7-(l-pyrrolidinyl)-5H-benzocyclohepten-2-yl]- and has the following formula in the art:

[0100]

[0101] In a particular embodiment, the inhibitor is CA-170 (or AUPM-170): an oral, small molecule immune checkpoint antagonist targeting programmed death ligand- 1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) (Liu et al 2015). Preclinical data of CA-170 are presented by Curis Collaborator and Aurigene on November at ACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

[0102] In some embodiments, the immune checkpoint inhibitor is an aptamer.Typically, the aptamers are directed against A2AR, B7-H3, B7-H4, BTLA, CTLA-4, CD277, IDO, KIR, PD-1, LAG-3, TIM-3 or VISTA.

[0103] In a particular embodiment, aptamers are DNA aptamers such as described in Prodeus et al 2015. A major disadvantage of aptamers as therapeutic entities is their poor pharmacokinetic profiles, as these short DNA strands are rapidly removed from circulation due to renal filtration. Thus, aptamers according to the invention are conjugated to with high molecular weight polymers such as polyethylene glycol (PEG). In a particular embodiment, the aptamer is an anti-PD-1 aptamer. Particularly, the anti-PD-1 aptamer is MP7 pegylated as described in Prodeus et al 2015.

[0104] Pharmaceutical composition:

[0105] The combination of the present invention for use according to the invention combined with classical treatment as described above may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions.

[0106] A further object of the present invention relates to a pharmaceutical composition comprising the combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody.

[0107] In particular, the present invention relates to to a pharmaceutical composition comprising the combination of an oncolytic virus encoding the mAb 20.1 obtainable from the hybridoma accessible under CNCM deposit number 1-4402 and of Vy9Vb2 T cells.

[0108] In a particular embodiment, the pharmaceutical composition according to the invention comprising i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) a classical treatment, as a combined preparation for use in the treatment of cancer.

[0109] In a particular embodiment, the pharmaceutical composition according to the invention comprising i) a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) a classical treatment, as a combined preparation for use in a method for improving cancer immunotherapy.The combination of y8 T cells and an oncolytic virus encoding an anti-butyrophilin antibody of the present invention as described above may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions. "Pharmaceutically" or "pharmaceutically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle, alone or in combination with another active principle, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings. Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intravitreal administration, intrathecal and intranasal administration forms and rectal administration forms. Typically, the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The polypeptide(or nucleic acid encoding thereof) can be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin. Sterile injectable solutions are prepared by incorporating the active polypeptides in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuumdrying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could bedissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

[0110] The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.

[0111] FIGURES:

[0112] Figure 1. Generation of an oncolytic vaccinia virus encoding the anti-BTNA3 antibody 20.1. (A) Overview of the general strategy. Tumor cells infected by the armed virus produce anti-BTNA3 agonistic antibodies that will bind to butyrophilins on neighboring tumor cells to activate y982 T lymphocytes. (B) The sequences encoding either the full-length anti-BTNA3 antibody 20.1 (VACV-FL-20.1), the scFv version of the 20.1 antibody (VACV-scFv-20.1) or the NLuciferase (VACV-NLuc) were inserted into the genome of the Western Reserve strain of VACV to replace the thymidine kinase (TK) gene. (C) Supernatants from BHK-21 cells left uninfected or infected by VACV-NLuc or VACV-FL-20.1 were analyzed by western-blot for expression of the 20.1 antibody. (D) BTN3A- / - HEK293 cells were transfected with the genes encoding for BTN3A1, BTN3A2 or BTN3A3. Transfected cells were then incubated with filtered supernatants from uninfected cells (NI) or cells infected by VACV-NLuc or VACV-FL-20.1. The fixation of the 20.1 antibody was analyzed by flow cytometry. (E) MDA-MB-231 (breast), Ml 13 (melanoma), H1975 (lung) and Mesol3 (mesothelioma) cells lines were infected with VACV-NLuc, VACV-FL-20.1 or VACV-scFv-20.1 and cell viability was analyzed for 72h.

[0113] Figure 2. Oncolytic vaccina virus coding for the antibody 20.1 activates human y6 T cells (A-B) Ml 13 melanoma cells were incubated with native (A) or concentrated (B) supernatants from cells left uninfected (NI), infected with VACV-NLuc, VACV-FL-20.1 or VACV-scFv- 20.1, purified 20.1 antibody (1 pg / mL) or zoledronate (100 pM). After 2 h, y982 T cells were added to the culture. CD 107a and CD25 surface expression were analyzed by flow cytometry after 4 h or 24 h, respectively. (C) Ml 13 (melanoma), Meso34 (mesothelioma), H1975 (lung) or MDA-MB-231 (breast) cell lines were left uninfected (NI), infected with VACV-NLuc, VACV-FL-20.1 or VACV-scFv-20.1, or treated with either the purified 20.1 antibody (1ug / mL) or zoledronate (100 11M). 24 h post-infection or 2 h post-treatment, y982 T cells were added to the culture and analyzed after 4 h by flow cytometry for CD 107a surface expression.

[0114] (D) M6, Ml 13, Meso 13, Meso34 and Hl 975 cell lines were treated as in (C). 24 h post-infection or 2 h post-treatment, y982 T cells were added to the culture and analyzed after 24 h by flow cytometry for CD25 expression. (E) Wild-type and BTN3A- / - HEK293 cells were incubated with supernatants from cells left uninfected (NI), infected with VACV-NLuc, VACV-FL-20.1 or VACV-scFv-20.1, purified 20.1 antibody (1 ug / mL) or zoledronate (100 iiM). After 2 h, y982 T cells were added to the culture. CD 107a surface expression was analyzed by flow cytometry after 4 h.

[0115] Figure 3. Oncolytic vaccinia viruses coding for the antibody 20.1 enhances the cytotoxic activity of y6 T cells in vitro and in vivo. (A) Meso34, H1975 and MDA-MB-231 cells were left uninfected (NI), infected with VACV-NFuc, VACV-FF-20.1 or VACV-scFv-20.1, or treated with purified 20.1 antibody (1 ug / mL). 24 h post-infection or 2 h post-treatment, y982 T cells were added to the culture at the indicated ratios (no y8 T cells, 5:1, 10:1). Tumor cell death was determined after 4 h. (B) Meso 13 grown as spheroids were left uninfected (NI), infected for 24 h with VACV-NFuc, VACV-FF-20.1 or VACV-scFv-20.1, or treated for 2 h with zoledronate (100 iiM) before adding y982 T cells to the culture. Cell lysis was determined over time by incorporation of a permeable dye. (C) Mesol3-Fuc grown as spheroids were left uninfected (NI), infected for 24 h with VACV-NFuc, VACV-FF-20.1 or VACV-scFv-20.1, or treated for 2 h with zoledronate (100 iiM) before adding y982 T cells to the culture. Cell lysis was determined at 48h by measuring the release of Fuc in the supernatants. (D) NSG mice were challenged with Ml 13 melanoma cells. Tumors were injected intratumorally with buffer saline (PBS) or VACV-FF-20.1 (107pfu) at days 0 and 20 (orange arrows) and intravenously with 5.106y8 T cells at days 5 and 25 (blue arrows). Tumor volumes were measured over time. * p < 0.01 at day 41.

[0116] EXAMPLE:

[0117] Materials & Methods

[0118] Cell culture

[0119] Peripheral Blood Mononuclear Cells (PBMCs) were purified from healthy donors (Etablissement Frangais du Sang, Nantes, France; ethics agreement CPDE-PEER-2022 09)using lymphocyte separation medium (Eurobio, Les Ulis, France). Remaining red blood cells were lyzed with ACK lysing buffer (Gibco, Carlsbad, CA). Vy9V82 T cells were amplified from PBMCs by treatment with zoledronic acid (1 ug / mL, Sigma- Aldrich) and recombinant human IL-2 (200 UI / mL, Peprotech) for 21 days. Further amplification of purified y8 T cells was performed with a nonspecific amplification protocol using irradiated PBMCs, Phytohemagglutinin-L (1 ug / mL, Sigma- Aldrich) and IL-2 (150 UI / mL).

[0120] Human malignant pleural mesothelioma cell lines (Meso4, Meso 11, Meso 13, Meso34, Meso96, Meso 163) were established in our laboratory from pleural effusions of patients (biocollection Ministere de 1’Enseignement Superieur et de la Recherche #DC-2011-1399 and Commission Nationale de 1’ Informatique et des Libertes #1657097)19 and previously characterized for their mutational status using targeted sequencing20. Human melanoma cell lines (M6, Ml 13), obtained from tumor biopsies (Biocollection PC - U892 - NL, CHU Nantes, France), were a kind gift from Nathalie Labarriere (INCIT, Nantes, France). Lung adenocarcinoma (H1975, A549), breast cancer (MDA-MB-231, MCF-7), BHK-21, LentiX and HEK cells were purchased from ATCC.

[0121] BTN3A- / - HEK (HEKsh284) and MDA-MB-231 were constructed by transfecting a plasmid coding for a shRNA targeting the BTN3A genes. Mesol3-Luc cells were generated by transducing Meso 13 with a the lentiviral vector encoding Nanoluciferase (pMX-NLuc).

[0122] Mesothelioma, melanoma, and lung adenocarcinoma cell lines were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Eurobio, Les Ulis, France). Breast cancer cell lines, BHK-21, LentiX and HEK cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco). Both media were supplemented with 10% heat-inactivated fetal calf serum (Coming, NY), 100 U / mL penicillin, 100 mg / mL streptomycin and 2 mM L-glutamine (all from Gibco). All cells were cultured at 37°C in a 5 % CO2 atmosphere and were routinely checked for mycoplasma contamination using PlasmoTest (Invivogen, San Diego, CA).

[0123] For transwell assays, MDA-MB-231 cells were seeded in 24-well plates and infected or not with MV. Two days later, y8 T cells were cocultured with tumor cells or separated by an insert (0.4uM). Four hours later, y8 T cells were recovered and analyzed by flow cytometry for CD 107a surface expression.For spheroid formation, Mesol3 or Mesol3-Luc cells were seed at 3 x 104 cells per well in a 96-well Nunclon sphere U bottom plate (Thermo Fisher Scientific). The plate was centrifuged 2 min at 800 x g and incubated at 37 °C in a 5 % CO2 atmosphere for 5 days.

[0124] Reagents

[0125] For activation controls, tumor cells were either treated with zoledronic acid (Sigma) at 20 iiM the day before or 100 iiM two hours before coculture with yb T cells. The purified 20.1 antibody (1 ug / mL) or a combination of Phorbol 12-myristate 13 -acetate (5 ng / mL) + ionomycine (500 ng / mL) (both from Sigma) were also added two hours before coculture. Medium with activation reagents was replaced by fresh medium before adding the yb T cells to the coculture.

[0126] Oncolytic viruses

[0127] The live-attenuated Schwarz strain of measles virus (MV) was produced as previously described21.

[0128] Wild-type VSV or VSVd51 (mutated in position 51 of the M protein ), empty or encoding for GFP or scFv-20.1 between the G and L genes, were obtained by reverse genetics of the Indiana strain. Briefly, BHK-21 cells were infected with the vaccinia virus MVA-T7 (a gift from Dr John Bell, Ottawa Hospital Research Institute, Ottawa, Canada) at a multiplicity of infection (MOI) = 1. Ninety minutes later, cells were transfected with pBS-N, pBS-P, pBS-L and either pVSV, pVSVd51-NLuc or pVSVd51-ScFv-20.1. Two days later, supernatant was filtered at 0.22 pm to remove contaminating MVA-T7 and added to new BHK-21 cells to confirm VSV rescue. After amplification, VSV was purified by ultracentrifugation of supernatant on a 10 % sucrose cushion (100,000 x g, 1 h). Viral titers were determined by plaque assay on BHK-21 cells.

[0129] The recombinant Western Reserve (WR) strain of vaccinia virus was purchased from ATCC (vr-1354) and modified by homologous recombination of the transgenes of interest into the J2R gene locus. Briefly, LentiX cells were infected with WT WR at MOI 0.1, and transfected with pVSG2-NLuc, pVSG2 -FL-20.1 or pVSG2-scFV-20.1 an hour later. Next day, cells were harvested and lyzed by freeze-thaw cycle. Cell lysates were used to infect U251 cells and after 1 hour the medium was replaced with fresh medium containing 1 % agarose (Sigma). GFP+ plaques were selected the next day and used to infect new cells. This step was repeated until complete purity of the recombinant virus was achieved. After amplification, VACV waspurified by ultracentrifugation of cell lysates on a 36 % sucrose cushion (21 000 x g, lh30). Viral titer was determined by plaque assay on U251 cells.

[0130] Flow cytometry

[0131] Cells were stained for 30 min at 4 °C in PBS 0.1 % BSA (Sigma) with the adapted antibodies and isotypes (see Table I). For CD107a staining, the antibody was added directly during the coculture in presence of Monensine (Sigma) to block reintemalization of the protein. After 3 washes to remove unbound antibodies, cells were fixed in PBS 4 % Paraformaldehyde (Electron Microscopy Science) for 10 min and analyzed with a BD FACSCanto II or BD Symphony (BD Biosciences). Analyses were performed using the Flow Jo vl0.8.1 software (BD Biosciences).

[0132] ELISA IFN-y secretion was measured in the supernatant of y8 T cells, cocultured 24 hours with MDA-MB-231 pre -infected or not with MV (MOI =2) or VSV (MOI 0.1), using an EEISA IFN-y kit (Invitrogen, Waltham, MA). Absorbance values at 450 nm and 570 nm were read using a Multiskan FC microplate reader (Thermo Scientific, Waltham, MA) and concentrations were calculated according to the manufacturer’s instructions.

[0133] Western-blotting

[0134] Thirty pF of supernatant was mixed with 10 pF of 4X Eaemmli buffer (Bio-Rad, Hercules, CA) for the detection of FE-20.1. For scFv-20.1 detection, P-mercaptoethanol was added to the mix and the samples were heated at 95 °C for 5 min. Proteins were separated on 4-20 % Bis-Tris gels (Genscript, Eeiden, Netherlands) at 200 V for 40 min and transferred onto PVDF membranes (Millipore, Burlington, MA) at 100 V for 60 min. Membranes were then blocked for 1 h at room temperature in Tris-buffered saline (TBS) 0.05 % Tween-20 + 3 % BSA or 5 % fat-free milk for FE-20.1 and scFv-20.1, respectively.

[0135] For FE-20.1, the membrane was incubated overnight at 4 °C with an anti-mouse antibody (115-036-072, Jackson ImmunoResearch, West Grove, PA) and then incubated with clarity Western ECE substrate (Bio-Rad, Hercules, CA) and imaged with a ChemiDoc Imaging System (BioRad, Hercules, CA). Detection of StrepTag for the scFv-20.1 was done according to the instruction of the manufacturer for chemiluminescent detection with StrepMAB classic HRP (2-1507-001, Iba, Gottingen, Germany). To avoid titration of the antibody, the ladder lanes were cut and separated during incubation.Transfection

[0136] HEKsh284 were transfected with plasmids containing the BTN3A1, BTN3A2 or BTN3A3 genes. Two days later, cells were harvested and incubated with supernatant concentrated 16 times by Vivaspin 5 MWCO (Sartorius) from HEKsh284 either left uninfected (NI) or infected with VACV-NLuc, VACV-FL-20.1, VSVd51-scFv-20.1 or purified 20.1. Staining of the full-length or scFv antibodies was performed with anti-mouse IgG or Anti-StrepTag, respectively. Cells were then analyzed by flow cytometry.

[0137] Viability assay

[0138] Cell lines were seeded at 2.5 x 104 cells / well in a 96-well plate, cultured for 24 h at 37°C and infected at MOI 0.1 with VACV-NLuc, VACV-FL-20.1 or VACV-scFv-20.1. Cell viability was measured 24, 48 or 72 h post-infection using the CellTiter Gio Luminescent cell viability assay (Promega). Luminescence was measured using a Fluoroskan (ThermoFisher Scientific). Each time point is normalized to the uninfected condition.

[0139] Cytotoxicity assays

[0140] Four hours after starting the coculture with y8 T cells, lysis buffer of the Toxilight kit (Lonza) was added in the positive control well and Tris acetate buffer to the other wells. After 15 minutes, 25 pl of medium was transferred into a 96-well white plate and mixed with 50 pl of adenylate kinase detection reagent. After 5 minutes, the luminescence was measured using a Fluoroskan (TermoFisher Scientific).

[0141] In vivo experiments

[0142] Eight-week old female NSG mice (NOD.Cg-PrkdcSCIDI12rgtmlWjl / SzJ, Charles River Laboratories ) were challenged subcutaneously (right flank) with 5 x lO6 M113 melanoma cells in 100 pl PBS. 30 and 50 days after, established tumors were treated either with intratumoral injection of PBS, 1 x 107 pfu of virus (VACV-NLuc or VV-F1-20.1) in 25 pL PBS. Five days after each intratumoral injection, 5 x 106 y8 T cells were injected intravenously in 100 pL PBS. Tumors were measured every 2-3 days with a digital caliper and the volumes were calculated as (length x width2) / 2. The mice were euthanized when the maximum tumor volume of 1,500 mm3 was reached, or when they showed alteration of their general state.

[0143] Statistical methodsData are represented as the mean ± standard deviation (SD) of biological replicates. For all experiments, when comparing 3 or more groups, statistical significance was determined using the Kruskal- Wallis test followed by Dunn’s multiple comparison test. When comparing two groups, statistical significance was determined using the Mann-Whitney test. Statistical analyses were performed using Prism 8.0 (GraphPad Software, Boston, MA).

[0144] Results

[0145] Human d T cells are partly activated by oncolytic MV-infected tumor cells

[0146] Previous studies showed that several immune cell subtypes can be activated upon contact with tumor cells infected by oncolytic viruses. We first investigated whether different lymphocyte subpopulations from PBMCs were activated by tumor cells infected by the Schwarz strain of Measles Virus (MV), the Indiana strain of Vesicular Stomatitis Virus (VSV) or the Western Reserve strain of Vaccinia Virus (VACV) by studying the surface expression of the degranulation marker CD 107a after 4 hours. Overall, we did not observe any significant activation in the CD3+ population for the three viruses, but MV induced a significant activation for CD3- / CD56+ cells and a slight increase of CD107a on CD3+ cells (Data not shown). When further investigating the CD3+ subpopulations, we found that some y8 T cells, in particular from the Vy9V82 subset in two donors, showed an increased CD 107a surface expression after being co-cultured with MV-infected tumor cells (Data not shown). Analysis of the CD69 activation marker confirmed that oncolytic MV was able to induce the reaction of several lymphocyte subpopulations from PBMCs (Data not shown).

[0147] To confirm the specific effect of MV on y8 T cells, we cocultured MV-infected MDA-MB-231 breast cancer cells with human Vy9V82 amplified from different healthy donors. We confirmed that this subpopulation of y8 T cells reacted to MV-infected tumor cells (Data not shown) and that the significant increase of surface CD 107a was specific to MV. The other activation markers CD25, IFN-y (Data not shown) and CD69 (Data not shown) showed a similar - though not statistically significant - increase. However, we did not observe any increase in the production of TNF-a nor any change in y8 T cell proliferation (data not shown). We extended our findings to another cancer type by testing the reactivity of y8 T cells to human mesothelioma cell lines (Data not shown). We confirmed that oncolytic MV infection induces an increase of the CD 107a marker on the surface of y8 T cells when exposed to MV-infected tumor cells.To understand how MV infection could induce the activation of Vy9V82 T cells, we first tested whether cell-cell contact was necessary. Using 0.4 um-porc membranes, we found that the increase of CD 107a surface expression only occurred when infected tumor cells and Vy9V82 T cells could physically interact (Data not shown). However, this activation does not rely on the TCR / BTN3A axis as BTN3A- / - tumor cells infected by MV were similarly able to activate Vy9V82 T cells (Data not shown). Similarly, we did not observe any overexpression of NKG2D ligands in MV-infected tumor cells that could explain a TCR-independent activation of these cells (Data not shown). We also tested different inhibitors of innate antiviral pathways but we were unable to identify any that was involved in this activation (Data not shown). We then hypothesized that infection of the y8 T cells by oncolytic MV may be responsible for this activation. As such, we observed that Vy9V82 T cells were partly infected 5 days following exposure to oncolytic MV-infected tumor cells and that expression on the MV-H protein on their surface correlated with an increase in CD25 expression (Data not shown). However, as described above, we did not observe any activation when exposing y8 T cells directly to MV or to supernatants from MV-infected cells, which means that cell-cell contact with MV-infected cells may be necessary to promote this phenomenon.

[0148] Altogether, these results demonstrate that infection of tumor cells with oncolytic VSV and VACV does not lead to spontaneous activation of human y8 T cells, and that oncolytic MV only induced a partial activation.

[0149] Recombinant oncolytic viruses produce functional antibodies to activate yd T cells

[0150] In order to improve the reactivity of human y8 T cells against tumor cells, we decided to encode an agonistic anti-butyrophilin antibody in OVs for it to be produced in the tumor microenvironment by OV-infected tumor cells (Figure 1A). The 20.1 antibody has been described in the literature to bind to butyrophilins and to provoke their recognition by the Vy9V82 TCR, which leads to killing of the targeted cells. The nucleotide sequence of the 20.1 antibody was inserted into the genome of the Western Reserve strain of VACV (Figure IB).

[0151] Two constructions were made, the first one containing the full sequences of both the heavy chain and the light chain linked by a T2A sequence (VACV-FL-20.1), and the second one the sequence of a scFv version of the antibody (VACV-scFv-20.1). In parallel, this scFv sequence was also inserted into the genome of VSVd51 (Data not shown). We first verified that human cells infected by the modified viruses were able to produce and secrete the antibodies (Figure 1C & Data not shown) and then confirmed that the antibodies produced upon viral infectionwere able to bind to their targets, as shown by the recognition of the three iso forms of BTN3A expressed in BTN3A- / - cells Figure ID & Data not shown). The armed viruses were finally tested for their oncolytic activity against human tumor cell lines of different tissue origins. The insertion of the full-length or scFv antibody sequences in the VACV genome resulted in a slight attenuation of its oncolytic activity against some tumor cell lines (Figure IE) but both viruses eventually retained their ability to kill all tested cells.

[0152] OVs encoding the anti-BTN3A antibody 20.1 promote d T cell reactivity against tumor cells To determine whether the anti-BTN3A antibodies produced through OV vectorization were able to activate yb T cells, we first produced supernatants from cells infected by either VACV-FL-20.1 or VACV-scFv-20.1. We observed that native supernatants lead to a limited activation of yb T cells for both viruses (Figure 2A). After concentration of the proteins, the supernatant containing the full-length version of the anti-BTN3 A antibody was as efficient as the purified 20.1 antibody or zoledronate to promote CD 107a, CD25 (Figure 2B) and CD69 (Data not shown) surface expression. In these conditions, the supernatants containing the scFv version of the antibody were less efficient than the ones containing the full-length version.

[0153] To mimic a therapeutic context, we next sought to study the activation of Vy9Vb2 T cells directly incubated with VACV-FL-20.1- or VACV-scFv-20.1 -infected tumor cells. We tested 8 tumor cell lines derived from 4 different cancer types (melanoma, mesothelioma, lung and breast adenocarcinoma). All cell lines infected by the armed VACV led to a strong activation of yb T cells, in particular when infected by VACV-FL-20.1 that was constantly as efficient as the purified 20.1 antibody to induced CD107a (Figure 2C & Data not shown) or CD25 (Figure 2D) surface expression. For all cell lines, the VACV-scFv-20.1 showed a lower efficacy than VACV-FL-20.1, similar to what was observed with VS Vd51-scFv-20.1 (Data not shown). We confirmed that the presence of BTN3A at the surface of target cells was absolutely necessary for this activation as BTN3A- / - cells were unable to activate yb T cells (Figure 2E), even if the variations in the levels of BTN3A on tumor cells appeared to be of little consequence (Data not shown).

[0154] Overall, these results demonstrate that the 20.1 antibody produced by VACV-FL-20.1 - and to a lesser extent VACV-scFv-20.1 and VSV-scFv-20.1 - is fully functional and efficiently activates Vy9Vb2 T cells against tumor cells.VACV-FL-20.1 enhances the cytotoxic activity of yd T cell in vitro and in vivo To confirm that the activation of Vy9V82 T cells actually resulted in the induction of their cytolytic activity, we first cocultured tumor cells infected or not by the different oncolytic VACV and tested two effectortarget ratios Figure 3A). Similarly to what was observed for activation, VACV-FL-20.1 was as efficient as the purified 20.1 antibody to induce tumor cell lysis by activated Vy9V82 T cells in these conditions.

[0155] It is widely described how the structure of the tumor microenvironment can impact the activity of cytotoxic T cells. To mimic such an environment, we generated 3D tumor spheroids that were subsequently infected by the different viruses, cocultured or not with Vy9V82 T cells and analyzed for the incorporation of a permeable probe in dying cells (Figure 3B). Similarly to what was observed in 2D culture, VACV-FL-20.1 promoted tumor cells lysis at a similar level as the positive control zoledronate, with a maximal cell lysis observed at approximately 48h after adding the y8 T cells. Here, the VACV-scFv-20.1 virus was also very efficient in inducing tumor cell lysis. Since y8 T cells also express butyrophilins on their surface, we could not completely rule out that the fixation of the 20.1 antibody would provoke fratricide killing and lead to the incorporation of the fluorescent probe in dying y8 T cells. To confirm our findings, we thus developed an alternative reporter system where Meso 13 tumor cells were modified to constitutively express Luciferase. Upon killing, tumor cells would release Luciferase, which can be quantified in the supernatants. When infected Meso-Luc spheroids with the different viruses and coculturing them with Vy9V82 T cells, we confirmed that VACV-FL-20.1 efficiently drove the specific killing of tumor cells by cytotoxic y8 T cells (Figure 3C).

[0156] Interestingly, in the different experiments on spheroids we observed that direct killing of tumor cells by the oncolytic VACV was very low compared to the effect of activated Vy9V82 T cells. Finally, we sought to determine whether VACV-FL-20.1 would retain its therapeutic activity in an in vivo model. Since the 20.1 recognizes human butyrophilins and activates human Vy9V82 T cells, we set up an experiment in an immunodeficient mouse model that we challenged subcutaneously with Ml 13 human melanoma cells. When tumors reached a size of 50 to 100 mm3, they were injected either with control saline buffer or 107 pfu VACV -FL-20.1. Five millions of amplified Vy9V82 T cells were injected intravenously 5 days later and a second cycle of treatment was administered 20 days later. We observed that only the combination of VACV-FL-20.1 and Vy9V82 T cells was able to control tumor growth compared to PBS or either VACV-FL-20.1 or Vy9V82 T cells used alone (Figure 3D). However, though perfectlysafe when used in immunocompetent models, VACV ultimately induced severe toxicities in the treated animals and we did not observe any benefit in survival (Data not shown). Nevertheless, this experiment confirms that VACV-FL-20.1 is able to activate Vy9V82 T cells in vivo by driving the production of the agonistic anti-BTN antibody 20.1 in the tumor microenvironment, which leads to tumor control.

[0157] Discussion

[0158] y8 T cells are important players of the antitumor and antiviral immune responses and are associated with positive response to cancer immunotherapy. Here, we sought to understand how tumor cells infected by different OVs were recognized by y8 T cells. Overall, OV-infected tumor cells were poor activators of y8 T cells even if we observed a partial activation when cells were infected by the oncolytic MV Schwarz strain, through a mechanism that still needs to be elucidated. To improve the y8 T cell response in the context of OV therapy, we modified an oncolytic VACV with the sequence of an agonistic anti-BTN antibody that was previously shown to promote the recognition of targeted cells by Vy9V82 T cells and their subsequent activation. We first confirmed that VACV-FL-20.1- or VACV-scFV-20.1 -infected tumor cells were able to produce significant amounts of the 20.1 antibody and that it was functional to drive the activation of Vy9V82 T cells against a variety of tumor cells. This activation resulted in tumor cell killing by Vy9V82 T cells both in 2D and 3D culture systems. Finally, we showed that this strategy could be applied in vivo as a combination of intratumoral VACV-FL-20.1 and systemic Vy9V82 T cells demonstrated a higher antitumor efficacy than each of the treatments used alone. Overall, our results demonstrate that armed OVs can be used to harness the antitumor activity of y8 T cells by directing their cytolytic properties towards infected and noninfected cells of the tumor microenvironment.

[0159] A first question arising from our findings is the mechanisms by which y8 T cells are activated when in contact with oncolytic MV-infected tumor cells. Even if our focus was mainly on y8 T cells, we actually observed that other lymphocyte populations showed a similar activation in our initial screen, in particular CD3- / CD56+ and CD3+ / CD56+ cells that can be identified as NK and NKT cells, respectively. This is in line with our results showing that the y8TCR / BTN axis does not seem to be involved, but it does not rule out that other receptors shared by these different populations may be responsible. We confirmed that a physical contact between the infected tumor cells and the Vy9V82 T cells was necessary. Indeed, exposing y8 T cells to either purified virus or supernatants from MV-infected tumor cells did not result in any activation(data not shown). A hypothesis may be that the cellular contact with viral proteins at the cell surface or that fusion and infection induced by this contact may induce a reaction by the yb T cells. Further experiments will be needed to decipher precisely the mechanisms at play in this response of Vy9Vb2 T cells to MV infection.

[0160] yb T cells display numerous advantages compared to other players of the antitumor immune response, including the detection of conserved proteins through their TCR and innate receptors independently of classical antigenic presentation pathways, which allows their use for allogeneic cell therapy22and make them less susceptible to immune escape, a quick response to a variety of stimuli, and a unique combination of cytolytic activity and immunostimulatory cytokine production. Several approaches have been recently developed to harness the immunotherapeutic potential of the yb T cells23. The development of antibodies targeting butyrophilins to promote Vy9Vb2 T cell activation is of particular interest and first-in-human data are very promising8. Nevertheless, treatments with non-vectorized antibodies always raise questions regarding both efficacy and safety, as is the case with the use of immune checkpoint inhibitors24. Indeed, butyrophilins are ubiquitously expressed proteins and systemically injected anti-BTN antibodies may fail to reach the tumor sites, which may largely decrease the overall efficacy of the treatment. As such, the development of vectorization strategies for these antibodies could improve the activation of yb T cells specifically in tumors.

[0161] Among the therapeutic vectors currently available for cancer therapy, OVs exhibit original properties that make them particularly suitable to deliver immunotherapeutic agents9: a specific tropism for tumor cells, a natural immunogenicity that activates numerous actors of the antitumor immune response and a competence for replication that can amplify their therapeutic effects over an extended period of time. A wide variety of viruses carrying immunotherapeutic transgenes, such as cytokines or antibodies, have been developed over the last decade and showed promising results both in preclinical and clinical studies16.

[0162] Our study shows that agonistic antibodies expressed in the tumor can activate yb T cells injected intravenously. Further studies will be needed in immunocompetent animal models to determine whether OVs modified or not are able to provoke the infiltration of endogenous yb T cells, drive their polarization towards an antitumor phenotype, induce their proliferation and maintain their cytolytic activity over time. The use of immunocompetent animals, which will better control the toxicities related to the use of replicating OV, may also allow us to investigate the efficacyof our therapeutic approach for a longer time and determine if it can also elicit a memory response.

[0163] An important question remains regarding the appropriate format of antibody to be used to optimize the therapeutic effects that we observed. In our experimental setting, the full-length version of the 20.1 antibody was consistently better than the scFv version, which correlates with the respective efficacies of the purified versions of the two formats that we observed in other experiments (data not shown). However, we cannot completely rule out that the observed differences may be due to the selection of certain viral clones, which may be more attenuated or could express lower amounts of proteins in infected tumor cells. Indeed, we observed variations in cell death induction, transgene expression, and recombinant protein production across different viruses and tumor cell lines. Further work is needed to determine whether the levels of 20.1 production correlate with the extent of Vy9V82 T cell activation. In 3D models and in tumors, the diffusion of the viruses and the antibodies may also be more limited and one could expect that the scFv format may be more efficient in this context.

[0164] To conclude, this study shows for the first time that the activity of y8 T cells can be manipulated in vivo by using OVs rationally designed to target specific y8 cell ligands in tumors. We also show that alternative immune populations can be targeted in the tumor microenvironment to improve the antitumor response and that immunotherapeutic strategies should not be limited to the activation of conventional aP T cells.

[0165] REFERENCES:

[0166] Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.

[0167] 1. Riley, R.S., June, C.H., Langer, R., and Mitchell, M.J. (2019). Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175-196. https: / / doi.org / 10.1038 / s41573-018-0006-z.

[0168] 2. Mensurado, S., Blanco-Dominguez, R., and Silva-Santos, B. (2023). The emerging roles of y8 T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178-191. https: / / doi.org / ! 0.1038 / s41571 -022-00722-1.3. Wu, D., Wu, P., Qiu, F., Wei, Q., and Huang, J. (2017). Human y8T-cell subsets and their involvement in tumor immunity. Cell. Mol. Immunol. 14, 245-253. https: / / doi.org / 10.1038 / cmi.2016.55.

[0169] 4. Sebestyen, Z., Prinz, I., Dechanet-Merville, J., Silva-Santos, B., and Kuball, J. (2020). Translating gammadelta (y8) T cells and their receptors into cancer cell therapies. Nat. Rev. Drug Discov. 19, 169-184. https: / / doi.org / 10.1038 / s41573-019-0038-z.

[0170] 5. Rafia, C., Harly, C., and Scotet, E. (2020). Beyond CAR T cells: Engineered Vy9V82 T cells to fight solid tumors. Immunol. Rev. 298, 117-133. https: / / doi.org / 10.llll / imr.12920.

[0171] 6. Herrmann, T., and Karunakaran, M.M. (2022). Butyrophilins: y8 T Cell Receptor Ligands, Immunomodulators and More. Front. Immunol. 13. https: / / doi.org / 10.3389 / fimmu.2022.876493.

[0172] 7. Rigau, M., Uldrich, A.P., and Behren, A. (2021). Targeting butyrophilins for cancer immunotherapy. Trends Immunol. 42, 670-680. https: / / doi.Org / 10.1016 / j.it.2021.06.002. 8. De Gassart, A., Le, K.-S., Brune, P., Agaugue, S., Sims, J., Goubard, A., Castellano, R., Joalland, N., Scotet, E., Collette, Y., et al. (2021). Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vy9V82 T cell-mediated antitumor immune response. Sci. Transl. Med. 13, eabj0835. https: / / doi.org / 10.1126 / scitranslmed.abj0835.

[0173] 9. Briolay, T., Petithomme, T., Fouet, M., Nguyen-Pham, N., Blanquart, C., and Boisgerault, N. (2021). Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Mol. Cancer 20, 55. https: / / doi.org / 10.1186 / sl2943-021-01346-2.

[0174] 10. Bommareddy, P.K., Shettigar, M., and Kaufman, H.L. (2018). Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol., 1. https: / / doi.org / 10.1038 / s41577-018-0014-6.

[0175] 11. Delaunay, T., Achard, C., Boisgerault, N., Grard, M., Petithomme, T., Chatelain, C., Dutoit, S., Blanquart, C., Royer, P.-J., Minvielle, S., et al. (2020). Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer, https : / / doi.org / 10.1016 / j .jtho .2019.12.128.

[0176] 12. Wang, L., Chard Dunmall, L.S., Cheng, Z., and Wang, Y. (2022). Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J. Immunother. Cancer 10, e004167. https: / / doi.org / 10.1136 / jitc-2021-004167.

[0177] 13. Guillerme, J.-B., Boisgerault, N., Roulois, D., Menager, J., Combredet, C., Tangy, F., Fonteneau, J.-F., and Gregoire, M. (2013). Measles Virus Vaccine-Infected Tumor CellsInduce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells. Clin. Cancer Res. 19, 1147-1158. https: / / doi.org / 10.1158 / 1078-0432.CCR-12-2733.

[0178] 14. Achard, C., Guillerme, J.-B., Bruni, D., Boisgerault, N., Combredet, C., Tangy, F., Jouvenet, N., Gregoire, M., and Fonteneau, J.-F. (2017). Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. Oncolmmunology 6, el 261240. https: / / doi.org / 10.1080 / 2162402X.2016.1261240.

[0179] 15. Delaunay, T., Violland, M., Boisgerault, N., Dutoit, S., Vignard, V., Munz, C., Gannage, M., Dreno, B., Vaivode, K., Pjanova, D., et al. (2018). Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. Oncolmmunology 7, M407897. https: / / doi.org / 10.1080 / 2162402X.2017.1407897.

[0180] 16. Shalhout, S.Z., Miller, D.M., Emerick, K.S., and Kaufman, H.L. (2023). Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160-177. https: / / d0i.0rg / l 0.1038 / s41571 -022-00719-w.

[0181] 17. Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., and Tanaka, M. (2022). Intratumoral oncolytic herpes virus G47A for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 1630-1639. https: / / doi.org / 10.1038 / s41591-022-01897-x.

[0182] 18. Li, R., Shah, P.H., Stewart, T.F., Nam, J.K., Bivalacqua, T.J., Lamm, D.L., Uchio, E.M., Geynisman, D.M., Jacob, J.M., Meeks, J.J., et al. (2024). Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat. Med., 1-8. https: / / doi.org / 10.1038 / s41591-024-03025-3.

[0183] 19. Gueugnon, F., Leclercq, S., Blanquart, C., Sagan, C., Cellerin, L., Padieu, M., Perigaud, C., Scherpereel, A., and Gregoire, M. (2011). Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am. J. Pathol. 178, 1033-1042. https : / / doi.org / 10.1016 / j . ajpath.2010.12.014.

[0184] 20. Quetel, L., Meiller, C., Assie, J., Blum, Y., Imbeaud, S., Montagne, F., Tranchant, R., de Wolf, J., Caruso, S., Copin, M., et al. (2020). Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol. Oncol. 14, 1207-1223. https: / / doi.org / 10.1002 / 1878-0261.12651.

[0185] 21. Combredet, C., Labrousse, V., Mollet, L., Lorin, C., Delebecque, F., Hurtrel, B., McClure, H., Feinberg, M.B., Brahic, M., and Tangy, F. (2003). A Molecularly Cloned Schwarz Strain of Measles Virus Vaccine Induces Strong Immune Responses in Macaques and Transgenic Mice. J. Virol. 77, 11546-11554. https: / / doi.org / 10.1128 / JVI.77.21.11546-11554.2003.22. Xu, Y., Xiang, Z., Alnaggar, M., Kouakanou, L., Li, J., He, J., Yang, J., Hu, Y., Chen, Y., Lin, L., et al. (2021). Allogeneic Vy9V82 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell. Mol. Immunol. 18, 427-439. https: / / doi.org / 10.1038 / s41423-020-0515-7.

[0186] 23. Revesz, LA., Joyce, P., Ebert, L.M., and Prestidge, C.A. (2024). Effective y <5 T - cell clinical therapies: current limitations and future perspectives for cancer immunotherapy. Clin. Transl. Immunol. 13, el492. https: / / doi.org / 10.1002 / cti2.1492.

[0187] 24. Johnson, D.B., Nebhan, C.A., Moslehi, J.J., and Balko, J.M. (2022). Immune-checkpoint inhibitors: long-term implications of toxicity. Nat. Rev. Clin. Oncol. 19, 254-267. https: / / doi.org / ! 0.1038 / s41571 -022-00600-w.

Claims

CLAIMS:

1. A combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody.

2. The combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody according to claim 1 wherein the oncolytic virus is measles virus (MV).

3. The combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody according to claim 1 wherein the oncolytic virus is vesicular stomatitis virus (VSV) or a recombinant vaccinia virus (VV).

4. The combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody according to claim 1 wherein the yb T cells are Vy9Vb2 T cells.

5. The combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody according to claim 1 wherein the anti-butyrophilin antibody is mAb 20.1 obtainable from the hybridoma accessible under CNCM deposit number 1-4402.

6. A combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody for use in therapy.

7. A method of treatment of cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody.

8. The method of treatment according to claim 7 wherein the anti-butyrophilin antibody is mAb 20.1 obtainable from the hybridoma accessible under CNCM deposit number I- 4402.

9. The method of treatment according to claim 7 wherein yb T cells are Vy9Vb2 T cells.

10. A vaccine for the treatment of a cancer comprising a combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody.

11. i) A combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) a classical treatment, as a combined preparation for use in the treatment of cancer.

12. i) A combination of yb T cells and an oncolytic virus encoding an anti-butyrophilin antibody and ii) a classical treatment, as a combined preparation for use in a method for improving cancer immunotherapy.